#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13230	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2529	645.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1920	1920	T	854	T,C,G	847,4,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13230	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2529	645.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1654	1654	C	856	C	856	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13230	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2529	645.5	0	HET	.	.	.	A69G,C	.	69	69	A	539	539	A	859	A,G,C	626,231,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22686	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4022	702.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1836	1836	A	965	A,G	964,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22686	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4022	702.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2470	2470	C	800	C,T,G	798,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22686	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4022	702.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2544	2544	A	704	A	704	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	22686	23S	2890	2890	99.93	23S.l15.c17.ctg.1	4022	702.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3096	3096	C	825	C,A,T	822,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2020	folP	852	852	99.88	folP.l15.c4.ctg.1	2048	123.0	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1067	1069	AAA	197;199;200	A;A;A	197;199;200	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2020	folP	852	852	99.88	folP.l15.c4.ctg.1	2048	123.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1298	1300	AGC	210;209;211	A;G;C	210;209;211	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4876	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3836	158.6	1	SNP	p	S91F	0	.	.	271	273	TCC	826	828	TCC	174;174;175	T;C,A;C	174;173,1;175	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4876	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3836	158.6	1	SNP	p	D95G	0	.	.	283	285	GAC	838	840	GAC	181;181;182	G;A,T;C,A	181;180,1;179,3	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4876	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3836	158.6	1	SNP	p	D95N	0	.	.	283	285	GAC	838	840	GAC	181;181;182	G;A,T;C,A	181;180,1;179,3	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1814	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1879	120.5	1	SNP	p	G45D	0	.	.	133	135	GGC	784	786	GGC	199;200;200	G;G;C	199;200;200	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	974	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1493	81.3	0	.	n	.	0	A197.	DEL	197	197	A	803	803	A	202	A	202	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4384	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3486	156.8	1	SNP	p	D86N	0	.	.	256	258	GAC	853	855	GAC	241;241;244	G;A,C;C	241;240,1;244	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4384	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3486	156.8	1	SNP	p	S87R	0	.	.	259	261	AGT	856	858	AGT	243;242;242	A,C;G;T	242,1;242;242	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4384	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3486	156.8	1	SNP	p	S87I	0	.	.	259	261	AGT	856	858	AGT	243;242;242	A,C;G;T	242,1;242;242	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4384	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3486	156.8	1	SNP	p	S87W	0	.	.	259	261	AGT	856	858	AGT	243;242;242	A,C;G;T	242,1;242;242	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	4384	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3486	156.8	1	SNP	p	S88P	0	.	.	262	264	TCC	859	861	TCC	240;238;240	T;C;C	240;238;240	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4036	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3093	162.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1776	1778	GGC	228;228;225	G;G;C,A	228;228;224,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	3594	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2900	154.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1464	1466	GCA	211;212;216	G;C,A;A,C	211;210,2;215,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3594	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2900	154.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1467	1469	ATC	215;217;217	A,C;T;C,A	214,1;217;216,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3594	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2900	154.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1479	1481	GTG	234;234;237	G;T,G;G	234;233,1;237	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3594	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2900	154.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1479	1481	GTG	234;234;237	G;T,G;G	234;233,1;237	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3594	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2900	154.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1983	1985	ACC	214;213;213	A;C,G;C	214;212,1;213	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3594	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2900	154.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2037	2039	GCG	195;198;200	G;C;G,T	195;198;199,1	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3594	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2900	154.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2037	2039	GCG	195;198;200	G;C;G,T	195;198;199,1	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3594	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2900	154.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2160	2162	GGC	194;196;193	G;G;C	194;196;193	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3594	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2900	154.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2169	2171	GGC	198;200;202	G;G;C	198;200;202	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	3594	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2900	154.6	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2187	2189	CTG	195;196;197	C;T;G	195;196;197	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5044	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3694	170.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1936	1938	CCG	199;202;202	C;C;G	199;202;202	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2392	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2098	141.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	743	743	C	194	C,T	193,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	25;26;27	T;T;A	25;26;27	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	48;48;48	C;A;T	48;48;48	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	48;48;48	A;G;T	48;48;48	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	48;48;48	T;A;C	48;48;48	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	3;3;3	G;A;C	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	4;4;4	A;T;C	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	4;4;4	T;C;G	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	4;4;4	G;C;C	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	4;4;4	A;G;C	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	4;4;4	G;C;C	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	226	90.27	porB1a.l15.c17.ctg.1	374	22.5	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	5;5;5	G;T;T	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	177	45.0	0	.	p	.	0	M18T	NONSYN	52	54	ATG	128	130	ACG	48;46;45	A;C;G	48;46;45	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	242	porB1a	984	100	94.0	porB1a.l15.c17.ctg.3	177	45.0	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	170	172	CAA	14;12;10	C;A;A	14;12;10	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2546	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1884	167.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	582	584	GAA	232;236;238	G,T,C,A;A;A	229,1,1,1;236;238	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2546	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1884	167.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	870	872	GAT	193;192;191	G,T;A;T	191,2;192;191	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2546	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1884	167.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	993	995	TCA	230;228;230	T,G;C,T;A	228,2;227,1;230	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2546	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1884	167.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1122	1124	GTC	228;226;225	G,A,T;T;C,G	226,1,1;226;224,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2546	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1884	167.6	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1134	1136	TCT	221;220;223	T;C,G;T	221;219,1;223	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2546	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1884	167.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1452	1454	GCA	206;204;203	G;C;A	206;204;203	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2546	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1884	167.6	1	SNP	p	G120K	1	.	.	358	360	AAG	828	830	AAG	212;208;210	A,T;A,C;G	211,1;207,1;210	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2546	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1884	167.6	1	SNP	p	A121D	1	.	.	361	363	GAC	831	833	GAC	210;205;205	G;A,G;C	210;204,1;205	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2546	porB1b	1047	1047	99.24	porB1b.l15.c30.ctg.1	1884	167.6	1	SNP	p	D121N	0	.	.	361	363	GAC	831	833	GAC	210;205;205	G;A,G;C	210;204,1;205	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9082	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5316	213.1	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2240	2242	AAT	227;225;222	A;A;T,G	227;225;221,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1344	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1375	121.4	1	SNP	p	V57M	1	.	.	169	171	ATG	689	691	ATG	233;231;230	A,G;T;G,T	232,1;231;229,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
